MTOR and renal cell adenocarcinoma: Seeing that PI3K inhibitors are currently in clinical development, our purpose was to assess co-expression of PI3K subunits, p110α and p85, and mTOR in RCC tumors in a quantitative fashion and study pharmacological co-inhibition of these targets in vitro.